DE69420970D1 - Impfstoff zubereitungen - Google Patents

Impfstoff zubereitungen

Info

Publication number
DE69420970D1
DE69420970D1 DE69420970T DE69420970T DE69420970D1 DE 69420970 D1 DE69420970 D1 DE 69420970D1 DE 69420970 T DE69420970 T DE 69420970T DE 69420970 T DE69420970 T DE 69420970T DE 69420970 D1 DE69420970 D1 DE 69420970D1
Authority
DE
Germany
Prior art keywords
pct
date feb
sec
vaccine composition
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69420970T
Other languages
English (en)
Other versions
DE69420970T2 (de
Inventor
Steven Neville Medev Chatfield
Mark Medeva Vaccine Re Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medeva Holdings BV
Original Assignee
Medeva Holdings BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medeva Holdings BV filed Critical Medeva Holdings BV
Publication of DE69420970D1 publication Critical patent/DE69420970D1/de
Application granted granted Critical
Publication of DE69420970T2 publication Critical patent/DE69420970T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DE69420970T 1993-08-12 1994-07-29 Impfstoff zubereitungen Expired - Fee Related DE69420970T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939316745A GB9316745D0 (en) 1993-08-12 1993-08-12 Vaccine compositions
PCT/GB1994/001646 WO1995005194A1 (en) 1993-08-12 1994-07-29 Vaccine compositions

Publications (2)

Publication Number Publication Date
DE69420970D1 true DE69420970D1 (de) 1999-11-04
DE69420970T2 DE69420970T2 (de) 2000-03-30

Family

ID=10740372

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69420970T Expired - Fee Related DE69420970T2 (de) 1993-08-12 1994-07-29 Impfstoff zubereitungen

Country Status (12)

Country Link
US (2) US6129922A (de)
EP (1) EP0714307B1 (de)
JP (1) JP3883203B2 (de)
KR (1) KR100341958B1 (de)
AT (1) ATE185073T1 (de)
AU (1) AU674983B2 (de)
DE (1) DE69420970T2 (de)
DK (1) DK0714307T3 (de)
ES (1) ES2139083T3 (de)
GB (1) GB9316745D0 (de)
GR (1) GR3032134T3 (de)
WO (1) WO1995005194A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316745D0 (en) * 1993-08-12 1993-09-29 Medeva Holdings Bv Vaccine compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
JP2003517452A (ja) 1999-02-05 2003-05-27 アルク−アベル・アー／エス 新規粘膜デリバリーシステム
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US20020051794A1 (en) 2000-08-09 2002-05-02 Alk-Abello A/S Novel parenteral vaccine formulations and uses thereof
KR20050044523A (ko) * 2001-11-19 2005-05-12 벡톤 디킨슨 앤드 컴퍼니 입자 형태의 약제학적 조성물
CA2468958C (en) 2001-12-19 2012-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
KR100748842B1 (ko) 2004-09-09 2007-08-13 주식회사한국야쿠르트 에이형 간염바이러스에 대한 항체 제조방법 및 그 응용

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE99331T1 (de) * 1989-09-08 1994-01-15 Takeda Chemical Industries Ltd Fusionsproteine und herstellung davon.
JPH03135923A (ja) * 1989-10-20 1991-06-10 Chemo Sero Therapeut Res Inst 百日咳毒素ｂオリゴマーの構成サブユニットを含有する経鼻接種ワクチン
US5294548A (en) * 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
US5549896A (en) * 1991-05-08 1996-08-27 Schweiz. Serum- & Impfinstitut Bern Hepatitis a virus strain, method for the isolation of new hepatitis a virus strains and hepatitis a vaccines
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
GB9316745D0 (en) * 1993-08-12 1993-09-29 Medeva Holdings Bv Vaccine compositions
WO1995021515A1 (en) 1994-02-03 1995-08-10 Analogic Corporation X-ray tomography system for and method of improving the quality of a scanned image
US5766906A (en) * 1994-07-11 1998-06-16 The University Of North Carolina At Chapel Hill Hepatitis A virus deletion mutants and vaccine formulations containing the same

Also Published As

Publication number Publication date
US20030007979A1 (en) 2003-01-09
ES2139083T3 (es) 2000-02-01
AU674983B2 (en) 1997-01-16
WO1995005194A1 (en) 1995-02-23
ATE185073T1 (de) 1999-10-15
KR960703619A (ko) 1996-08-31
KR100341958B1 (ko) 2003-03-15
AU7235694A (en) 1995-03-14
DE69420970T2 (de) 2000-03-30
US6129922A (en) 2000-10-10
EP0714307B1 (de) 1999-09-29
GR3032134T3 (en) 2000-04-27
JPH09501437A (ja) 1997-02-10
US6699480B2 (en) 2004-03-02
EP0714307A1 (de) 1996-06-05
GB9316745D0 (en) 1993-09-29
JP3883203B2 (ja) 2007-02-21
DK0714307T3 (da) 2000-04-10

Similar Documents

Publication Publication Date Title
FI944676A0 (fi) Rokotteita, jotka sisältävät ionisoitumattomia pinta-aktiivisten aineiden vesikkeleitä
PT101052A (pt) Proteinas hibridas uteis na preparacao de vacinas
ATE350057T1 (de) Impfstoffzusammesetzung
DE69420970D1 (de) Impfstoff zubereitungen
ATE310014T1 (de) Hepatitis b-impfstoff
FI924457A (fi) Kompositioner och behandlingsfoerfarande foer lunginflammation i djur
WO2001060404A3 (en) Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens
KR920004422A (ko) Hiv의 주요 중화 결정인자
ATE154244T1 (de) Induzierung eines schutzes gegen virale infektionen
CA2168885A1 (en) Vaccine compositions
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
DE68922540D1 (de) Vorläufer des Hüllenglykoproteins des HIV-2 Retrovirus und verwandte Antigene.
KR20040000401A (ko) Ｈｉｖ 바이러스에 대한 천연 항체
ATE204761T1 (de) Pharmazeutische antigen-/antikörperpräparation

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee